Jens Grueger, PhD is the 2019-2020 President Elect for the Professional Society for Health Economics and Outcomes Research (ISPOR) and current Director and Partner at Boston Consulting Group in Zurich, Switzerland where he is the senior expert for pricing and market access in the life sciences. Previously, Dr Grueger was Head of Global Access at F. Hoffmann-La Roche, based in Basel, Switzerland. With his team, they drove holistic access strategies to ensure that Roche and healthcare systems deliver rapid, broad, and sustainable patient access to the company’s innovative offerings.
Dr. Grueger served for a number of years as the Novartis and then the Roche global representative to the UW School of Pharmacy Corporate Advisory Board. Jens has worked with and supported many CHOICE Institute initiatives. He has lectured in our classes and participated in several research projects with Drs. Sean Sullivan and Lou Garrison including recent work with ICER on appropriate cost-effectiveness thresholds in the United States (learn more from the associated webinar series here: https://icer-review.org/blog/webinar-series-ce-thresholds/)
Jens was trained in mathematics and medicine, receiving a master’s degree in medical statistics (1984) and a PhD in theoretical statistics (1986) from the Technical University of Dortmund in Germany. He started his professional career as a health systems researcher, consulting with governments and payers (1986-1994). He led country, regional, and global health economics and outcomes research, pricing, and access organizations for SmithKline Beecham (1994-1999), Novartis (1999-2009), Pfizer (2009-2011) and Roche (2011-2019). He built on the principles of health economics when driving value-based pricing in order to accelerate and broaden access for patients to innovative medicines. He has been promoting risk sharing, performance-based pricing, indication-based pricing, and international differential pricing. He has been leading innovative projects to engage with health technology assessment, payers, and patients around scientific advice, joint clinical scientific assessment, and innovative approaches to evidence generation including real-world data.
Dr Grueger has been an active ISPOR member since 1999, serving on the ISPOR Board of Directors from 2004-2006. He was a member of the ISPOR task force on real-world data (2005-2007), and performance-based risk-sharing arrangements (2011-2013). He participated in scientific committees, workshop committees, and abstract review committees for ISPOR conferences. He has been invited twice to present in plenary sessions at ISPOR Europe conferences (2011 and 2016), chair work groups, and contribute to numerous issues panels. He has been a member of the ISPOR Nominations Committee for the last 2 years, and since 2018 has participated in the ISPOR Strategic Plan Work Group. He has been a scientific reviewer for Value in Health for many years.
We welcome Dr. Grueger to the UWSOP and look forward to our continued collaboration. Learn more about Dr. Grueger and his vision for ISPOR during his tenure as president: https://www.ispor.org/about/our-leaders/jens-grueger
Faculty Link: https://sop.washington.edu/people/jens-grueger/